<DOC>
	<DOC>NCT02153073</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and efficacy of long-term use of granular capsule formulation of omega-3 fatty acid ethyl esters (Lotriga Granular Capsules) in patients with hyperlipidemia in daily medical practice</brief_summary>
	<brief_title>Evaluation of the Safety and Efficacy of Long-term Use of Lotriga</brief_title>
	<detailed_description>This special drug use surveillance on long-term use of granular capsule formulation of omega-3 fatty acid ethyl esters (Lotriga Granular Capsules) was designed to investigate the frequency of adverse events in patients with hyperlipidemia The usual adult dosage is 2 g of omega-3 fatty acid ethyl esters administered orally once daily after meals. However, the dosage can be increased up to twice daily (at a dose of 2 g) depending on the patient's triglyceride level.</detailed_description>
	<mesh_term>Hyperlipidemias</mesh_term>
	<criteria>Patients with hyperlipidemia (1) Patients with hemorrhage (e.g., hemophilia, capillary fragility, gastrointestinal ulcer, urinary tract hemorrhage, hemoptysis, or vitreous hemorrhage) (2) Patients with a history of hypersensitivity to ingredients in Lotriga Granular Capsules</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Pharmacological therapy</keyword>
</DOC>